JP2025514066A - 結晶形 - Google Patents

結晶形 Download PDF

Info

Publication number
JP2025514066A
JP2025514066A JP2024561794A JP2024561794A JP2025514066A JP 2025514066 A JP2025514066 A JP 2025514066A JP 2024561794 A JP2024561794 A JP 2024561794A JP 2024561794 A JP2024561794 A JP 2024561794A JP 2025514066 A JP2025514066 A JP 2025514066A
Authority
JP
Japan
Prior art keywords
compound
formula
adduct
crystalline form
qtx125
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024561794A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025514066A5 (https=
Inventor
サラザール、ヨス イオン ヴァラ
アレヴァロ、エネコ アルダバ
イグレシアス、タマラ ベッロ
ブエラ、ラウレアノ シモン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quimatryx SL
Original Assignee
Quimatryx SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quimatryx SL filed Critical Quimatryx SL
Publication of JP2025514066A publication Critical patent/JP2025514066A/ja
Publication of JP2025514066A5 publication Critical patent/JP2025514066A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01098—Histone deacetylase (3.5.1.98), i.e. sirtuin deacetylase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Peptides Or Proteins (AREA)
JP2024561794A 2022-04-19 2022-05-04 結晶形 Pending JP2025514066A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210409814.5A CN114634489B (zh) 2022-04-19 2022-04-19 结晶形式
CN202210409814.5 2022-04-19
PCT/EP2022/062061 WO2023202787A1 (en) 2022-04-19 2022-05-04 Crystalline forms

Publications (2)

Publication Number Publication Date
JP2025514066A true JP2025514066A (ja) 2025-05-02
JP2025514066A5 JP2025514066A5 (https=) 2025-05-13

Family

ID=81940491

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024561794A Pending JP2025514066A (ja) 2022-04-19 2022-05-04 結晶形

Country Status (6)

Country Link
US (1) US20260070895A1 (https=)
EP (1) EP4511124A1 (https=)
JP (1) JP2025514066A (https=)
CN (1) CN114634489B (https=)
TW (1) TWI850657B (https=)
WO (1) WO2023202787A1 (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008534436A (ja) * 2005-04-07 2008-08-28 帝人ファーマ株式会社 アミノピロリジン誘導体の結晶及びその製造方法
JP2013506637A (ja) * 2009-10-02 2013-02-28 イケルケム、エセ エレ 三置換１ｈ−ピロール類と、芳香族スペーサーおよびヘテロ芳香族スペーサーとに同時に基づく新規ヒストンデアセチラーゼ阻害剤
JP2018525436A (ja) * 2015-07-24 2018-09-06 シェンチェン インスティチュート オブ シィァンヤー バイオメディシン オービットアジン−フマル酸塩、水和物、結晶形及びその調製方法
JP2019521980A (ja) * 2016-06-16 2019-08-08 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. Ｊａｋ阻害剤としてのピロロピリミジン化合物の結晶

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
EP3318256A1 (en) 2016-11-08 2018-05-09 Quimatryx, S.L Compounds for the treatment of autoimmune diseases
AU2020259100B2 (en) * 2019-04-17 2024-12-12 Fundación Kertor 1,3,4-oxadiazole derivatives as histone deacetylase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008534436A (ja) * 2005-04-07 2008-08-28 帝人ファーマ株式会社 アミノピロリジン誘導体の結晶及びその製造方法
JP2013506637A (ja) * 2009-10-02 2013-02-28 イケルケム、エセ エレ 三置換１ｈ−ピロール類と、芳香族スペーサーおよびヘテロ芳香族スペーサーとに同時に基づく新規ヒストンデアセチラーゼ阻害剤
JP2018525436A (ja) * 2015-07-24 2018-09-06 シェンチェン インスティチュート オブ シィァンヤー バイオメディシン オービットアジン−フマル酸塩、水和物、結晶形及びその調製方法
JP2019521980A (ja) * 2016-06-16 2019-08-08 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. Ｊａｋ阻害剤としてのピロロピリミジン化合物の結晶

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
平山令明, 有機化合物結晶作製ハンドブック, JPN6014035600, 2008, pages 17 - 23, ISSN: 0005782417 *
芦澤 一英: "塩・結晶形の最適化と結晶化技術", PHARM TECH JAPAN, vol. 18, no. 10, JPN6013060608, 2002, pages 81 - 96, ISSN: 0005782418 *
高田則幸: "創薬段階における原薬Formスクリーニングと選択", PHARM STAGE, vol. 6, no. 10, JPN6009053755, 15 January 2007 (2007-01-15), pages 20 - 25, ISSN: 0005782419 *

Also Published As

Publication number Publication date
TWI850657B (zh) 2024-08-01
EP4511124A1 (en) 2025-02-26
CN114634489A (zh) 2022-06-17
US20260070895A1 (en) 2026-03-12
CN114634489B (zh) 2023-07-04
TW202342460A (zh) 2023-11-01
WO2023202787A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
JP3148223B2 (ja) ラクタムフリーのアミノ酸
AU2003261748B2 (en) Benzenesulfonate of 4-fluoro-2-cyanopyrrolidine derivative
TW200403210A (en) Benzamide derivatives
ES2382806T3 (es) Compuesto ácido ciclohexanocarboxílico
KR102791742B1 (ko) (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복실산의 합성을 위한 공정
TW201619142A (zh) 利用替唑尼特（ｔｉｚｏｘａｎｉｄｅ）、其類似物或鹽類之前驅藥的組成物及治療方法
CN105073740B (zh) 一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途
NZ578854A (en) Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms
ES2982217T3 (es) Antagonistas de DP
JPH10506410A (ja) 抗腫瘍剤及び抗ウイルス剤としてのビス−（２−ハロエチル）アミノフェニル置換ジスタマイシン誘導体
JP2025514066A (ja) 結晶形
EP0703915B1 (en) Xamoneline tartrate
CN101506169A (zh) 马来酸氟吡汀的药学可接受的盐及多晶型物
HK40066780A (zh) 结晶形式
ES2371848B1 (es) Co-cristales de tramadol y paracetamol.
HK40066780B (en) Crystalline forms
CN110548005B (zh) 含有多奈哌齐衍生物的缓释注射制剂
TW201922690A (zh) 環－amp反應元素結合蛋白的抑制劑
CN110740988A (zh) 制备l-鸟氨酸苯乙酸盐的方法
CA2887420C (en) Matrix metalloproteinase inhibitors and methods for the treatment of pain and other diseases
CN115260107B (zh) 一种抗肿瘤药物前药、药物组合物及在肿瘤靶向治疗领域的应用
WO2019110006A1 (zh) 抗疼痛化合物及其制备方法
JPS606672A (ja) 喘息治療法
JPH06505699A (ja) 精神活性薬及び治療
JPS59231057A (ja) カルボン酸アミド化合物およびその誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260423